Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 936

1.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.

Sepriano A, Kerschbaumer A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, McInnes IB, Bijlsma JW, Burmester GR, de Wit M, Falzon L, Landewé R.

Ann Rheum Dis. 2020 Feb 7. pii: annrheumdis-2019-216653. doi: 10.1136/annrheumdis-2019-216653. [Epub ahead of print]

PMID:
32033941
2.

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.

Kerschbaumer A, Sepriano A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, McInnes IB, Bijlsma JWJ, Burmester GR, de Wit M, Falzon L, Landewé R.

Ann Rheum Dis. 2020 Feb 7. pii: annrheumdis-2019-216656. doi: 10.1136/annrheumdis-2019-216656. [Epub ahead of print]

3.

Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).

Chandran V, van der Heijde D, Fleischmann RM, Lespessailles E, Helliwell PS, Kameda H, Burgos-Vargas R, Erickson JS, Rathmann SS, Sprabery AT, Birt JA, Shuler CL, Gallo G.

Rheumatology (Oxford). 2020 Feb 7. pii: kez684. doi: 10.1093/rheumatology/kez684. [Epub ahead of print]

PMID:
32031665
4.

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research.

van der Heijde D, Gladman DD, Kavanaugh A, Mease PJ.

Arthritis Res Ther. 2020 Feb 3;22(1):18. doi: 10.1186/s13075-020-2103-8. Review.

5.

Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis.

Sundin U, Aga AB, Skare Ø, Nordberg LB, Uhlig T, Hammer HB, van der Heijde D, Kvien TK, Lillegraven S, Haavardsholm EA; ARCTIC study group .

Rheumatology (Oxford). 2020 Jan 30. pii: kez674. doi: 10.1093/rheumatology/kez674. [Epub ahead of print]

PMID:
31999341
6.

Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial.

Emery P, Horton S, Dumitru RB, Naraghi K, van der Heijde D, Wakefield RJ, Hensor EMA, Buch MH.

Ann Rheum Dis. 2020 Jan 29. pii: annrheumdis-2019-216539. doi: 10.1136/annrheumdis-2019-216539. [Epub ahead of print]

7.

What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts.

Sepriano A, Ramiro S, van der Heijde D, van Gaalen F, Hoonhout P, Molto A, Saraux A, Ramonda R, Dougados M, Landewé R.

Ann Rheum Dis. 2020 Mar;79(3):324-331. doi: 10.1136/annrheumdis-2019-216516. Epub 2020 Jan 24.

PMID:
31980546
8.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.

Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D.

Ann Rheum Dis. 2020 Jan 22. pii: annrheumdis-2019-216655. doi: 10.1136/annrheumdis-2019-216655. [Epub ahead of print]

9.

Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial.

Michielsens CAJ, Boers N, den Broeder N, Wenink MH, van der Maas A, Mahler EAM, Mulder MLM, van der Heijde D, van den Hoogen FHJ, Verhoef LM, den Broeder AA.

Trials. 2020 Jan 15;21(1):90. doi: 10.1186/s13063-019-4000-5.

10.

Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis: 104-week results from the randomized controlled EMBARK study.

Dougados M, van der Heijde D, Tsai WC, Saaibi D, Marshall L, Jones H, Pedersen R, Vlahos B, Tarallo M.

Health Qual Life Outcomes. 2020 Jan 3;18(1):4. doi: 10.1186/s12955-019-1260-4.

11.

Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.

Strand V, van der Heijde D, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R; ORAL Scan investigators.

Clin Exp Rheumatol. 2019 Dec 19. [Epub ahead of print]

12.

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.

Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J; COAST-X Study Group.

Lancet. 2020 Jan 4;395(10217):53-64. doi: 10.1016/S0140-6736(19)32971-X. Epub 2019 Dec 5.

PMID:
31813637
13.

Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis.

López-Medina C, Ramiro S, van der Heijde D, Sieper J, Dougados M, Molto A.

RMD Open. 2019 Nov 21;5(2):e001108. doi: 10.1136/rmdopen-2019-001108. eCollection 2019.

14.

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.

van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, Wang X, Chu AD, Sieper J.

Lancet. 2019 Dec 7;394(10214):2108-2117. doi: 10.1016/S0140-6736(19)32534-6. Epub 2019 Nov 12.

PMID:
31732180
15.

Inhibition of spinal bone formation in AS: 10 years after comparing adalimumab to OASIS.

van der Heijde D, Landewé R.

Arthritis Res Ther. 2019 Nov 6;21(1):225. doi: 10.1186/s13075-019-2045-1.

16.

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).

Dougados M, Wei JC, Landewé R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS; COAST-V and COAST-W Study Groups.

Ann Rheum Dis. 2020 Feb;79(2):176-185. doi: 10.1136/annrheumdis-2019-216118. Epub 2019 Nov 4.

17.

Association of lumbosacral transitional vertebra and sacroiliitis in patients with inflammatory back pain suggesting axial spondyloarthritis.

Carvajal Alegria G, Voirin-Hertz M, Garrigues F, Herbette M, Deloire L, Simon A, Feydy A, Reijnierse M, van der Heijde D, Marhadour T, Saraux A.

Rheumatology (Oxford). 2019 Oct 31. pii: kez520. doi: 10.1093/rheumatology/kez520. [Epub ahead of print]

PMID:
31670801
18.

Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA study.

Stolwijk C, Essers I, van den Bosch F, Dougados M, Etcheto A, van der Heijde D, Landewé R, Molto A, van Tubergen A, Boonen A.

Rheumatology (Oxford). 2019 Oct 26. pii: kez482. doi: 10.1093/rheumatology/kez482. [Epub ahead of print]

PMID:
31665462
19.

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis.

Kiltz U, Landewé RBM, van der Heijde D, Rudwaleit M, Weisman MH, Akkoc N, Boonen A, Brandt J, Carron P, Dougados M, Gossec L, Jongkees M, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compán V, Niederman K, Sampaio-Barros PD, Slobodin G, Van den Bosch FE, van Tubergen A, van Weely S, Wiek D, Braun J.

Ann Rheum Dis. 2020 Feb;79(2):193-201. doi: 10.1136/annrheumdis-2019-216034. Epub 2019 Oct 11.

20.

Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.

van der Heijde D, Mease PJ, Landewé RBM, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Zhu X, Ligozio G, Readie A, Mpofu S, Pricop L.

Rheumatology (Oxford). 2019 Oct 5. pii: kez420. doi: 10.1093/rheumatology/kez420. [Epub ahead of print]

PMID:
31586420
21.

Self-reported painful joint count and assessor-reported tender joint count as instruments to assess pain in hand osteoarthritis.

Kroon FPB, Damman W, van der Plas JL, van Beest S, Rosendaal FR, van der Heijde D, Kloppenburg M.

Rheumatology (Oxford). 2019 Sep 19. pii: kez395. doi: 10.1093/rheumatology/kez395. [Epub ahead of print]

PMID:
31535691
22.

Adherence to Treat-to-target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort.

Sepriano A, Ramiro S, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Elkayam O, Thorne JC, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Schaeverbeke T, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Berner Hammer H, Paschke J, Dadashova R, Hutchings E, Landewé R, Maksymowych WP.

J Rheumatol. 2019 Sep 15. pii: jrheum.190303. doi: 10.3899/jrheum.190303. [Epub ahead of print]

PMID:
31523049
23.

Reliability of Magnetic Resonance Imaging (MRI)-scoring of the Metatarsophalangeal-joints of the Foot According to the Rheumatoid Arthritis-MRI Score (RAMRIS).

Dakkak YJ, Matthijssen XME, van der Heijde DM, Reijnierse M, van der Helm-van Mil AHM.

J Rheumatol. 2019 Sep 15. pii: jrheum.190258. doi: 10.3899/jrheum.190258. [Epub ahead of print]

PMID:
31523041
24.

The effect of tumour necrosis factor inhibitors on radiographic progression in axial spondyloarthritis: a systematic literature review.

Boers N, Michielsens CAJ, van der Heijde D, den Broeder AA, Welsing PMJ.

Rheumatology (Oxford). 2019 Nov 1;58(11):1907-1922. doi: 10.1093/rheumatology/kez363.

PMID:
31518426
25.

Outcomes and Findings of the International Rheumatoid Arthritis (RA) BIODAM Cohort for Validation of Soluble Biomarkers in RA.

Maksymowych WP, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Lambert RG, Elkayam O, Ramiro S, Thorne JC, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Schaeverbeke T, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Berner Hammer H, Paschke J, Dadashova R, Hutchings E, Sepriano A, Landewé R.

J Rheumatol. 2019 Sep 1. pii: jrheum.190302. doi: 10.3899/jrheum.190302. [Epub ahead of print]

PMID:
31474600
26.

Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes.

Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA, Ramamoorthi N, John CR, Watson DS, Kummerfeld SK, Hands R, Riahi S, Rocher-Ros V, Rivellese F, Humby F, Kelly S, Bombardieri M, Ng N, DiCicco M, van der Heijde D, Landewé R, van der Helm-van Mil A, Cauli A, McInnes IB, Buckley CD, Choy E, Taylor PC, Townsend MJ, Pitzalis C.

Cell Rep. 2019 Aug 27;28(9):2455-2470.e5. doi: 10.1016/j.celrep.2019.07.091.

27.

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.

Genovese MC, van der Heijde D, Lin Y, St John G, Wang S, van Hoogstraten H, Gómez-Reino JJ, Kivitz A, Maldonado-Cocco JA, Seriolo B, Stanislav M, Burmester GR.

RMD Open. 2019 Aug 1;5(2):e000887. doi: 10.1136/rmdopen-2018-000887. eCollection 2019.

28.

MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group.

Maksymowych WP, Lambert RG, Østergaard M, Pedersen SJ, Machado PM, Weber U, Bennett AN, Braun J, Burgos-Vargas R, de Hooge M, Deodhar AA, Eshed I, Jurik AG, Hermann KA, Landewé RB, Marzo-Ortega H, Navarro-Compán V, Poddubnyy D, Reijnierse M, Rudwaleit M, Sieper J, Van den Bosch FE, van der Heijde D, van der Horst-Bruinsma IE, Wichuk S, Baraliakos X.

Ann Rheum Dis. 2019 Nov;78(11):1550-1558. doi: 10.1136/annrheumdis-2019-215589. Epub 2019 Aug 17.

PMID:
31422357
29.

Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts.

Boel A, Molto A, van der Heijde D, Ciurea A, Dougados M, Gensler LS, Santos MJ, De Miguel E, Poddubnyy D, Rudwaleit M, van Tubergen A, van Gaalen FA, Ramiro S.

Ann Rheum Dis. 2019 Nov;78(11):1545-1549. doi: 10.1136/annrheumdis-2019-215707. Epub 2019 Jul 30.

30.

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.

Takeuchi T, Tanaka Y, Tanaka S, Kawakami A, Iwasaki M, Katayama K, Rokuda M, Izutsu H, Ushijima S, Kaneko Y, Shiomi T, Yamada E, van der Heijde D.

Ann Rheum Dis. 2019 Oct;78(10):1305-1319. doi: 10.1136/annrheumdis-2019-215164. Epub 2019 Jul 26.

31.

Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.

Fleischmann R, Genovese MC, Lin Y, St John G, van der Heijde D, Wang S, Gomez-Reino JJ, Maldonado-Cocco JA, Stanislav M, Kivitz AJ, Burmester GR.

Rheumatology (Oxford). 2020 Feb 1;59(2):292-302. doi: 10.1093/rheumatology/kez265.

PMID:
31312844
32.

Low specificity but high sensitivity of inflammatory back pain criteria in rheumatology settings in Europe: confirmation of findings from a German cohort study.

de Hooge M, van Gaalen FA, Renson T, De Craemer AS, van de Sande MG, Ramonda R, Fagerli KM, Jacobsson LTH, van der Heijde D, Elewaut D, Van den Bosch F.

Ann Rheum Dis. 2019 Nov;78(11):1605-1606. doi: 10.1136/annrheumdis-2019-215742. Epub 2019 Jul 13. No abstract available.

PMID:
31302595
33.

Associations of lumbar scoliosis with presentation of suspected early axial spondyloarthritis.

Voirin-Hertz M, Carvajal Alegria G, Garrigues F, Simon A, Feydy A, Reijnierse M, van der Heijde D, Loeuille D, Claudepierre P, Marhadour T, Saraux A.

Semin Arthritis Rheum. 2020 Feb;50(1):48-53. doi: 10.1016/j.semarthrit.2019.06.008. Epub 2019 Jun 13.

PMID:
31277929
34.

Development of one general and six country-specific algorithms to assess societal health utilities based on ASAS HI.

Essers I, Hiligsmann M, Kiltz U, Bansback N, Braun J, van der Heijde D, Boonen A.

RMD Open. 2019 May 21;5(1):e000872. doi: 10.1136/rmdopen-2018-000872. eCollection 2019.

35.

Spinal-pelvic orientation: potential effect on the diagnosis of spondyloarthritis.

Carvajal Alegria G, Deloire L, Herbette M, Garrigues F, Gossec L, Simon A, Feydy A, Reijnierse M, van der Heijde D, Loeuille D, Claudepierre P, Marhadour T, Saraux A.

Rheumatology (Oxford). 2020 Jan 1;59(1):84-89. doi: 10.1093/rheumatology/kez240.

PMID:
31236597
36.

Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison.

Braun J, Haibel H, de Hooge M, Landewé R, Rudwaleit M, Fox T, Readie A, Richards HB, Porter B, Martin R, Poddubnyy D, Sieper J, van der Heijde D.

Arthritis Res Ther. 2019 Jun 7;21(1):142. doi: 10.1186/s13075-019-1911-1.

37.

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis.

van der Heijde D, Schiff M, Tanaka Y, Xie L, Meszaros G, Ishii T, Casillas M, Ortmann RA, Emery P.

RMD Open. 2019 May 10;5(1):e000898. doi: 10.1136/rmdopen-2019-000898. eCollection 2019. Erratum in: RMD Open. 2019 Jul 8;5(2):e000898corr1.

38.

Correction: HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort.

de Winter JJ, Blijdorp IC, de Jong HM, Sauter J, Schmidt AH, van Gaalen FA, van der Heijde D, Poddubnyy D, Yeremenko NG, van de Sande MG, Baeten DL.

Genes Immun. 2019 Nov;20(8):690. doi: 10.1038/s41435-019-0076-x.

PMID:
31068685
39.

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.

Takeuchi T, Tanaka Y, Soen S, Yamanaka H, Yoneda T, Tanaka S, Nitta T, Okubo N, Genant HK, van der Heijde D.

Ann Rheum Dis. 2019 Jul;78(7):899-907. doi: 10.1136/annrheumdis-2018-214827. Epub 2019 Apr 29.

40.

Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known?

van Lunteren M, van der Heijde D, Sepriano A, Berg IJ, Dougados M, Gossec L, Jacobsson L, Ramonda R, Rudwaleit M, Sieper J, Landewé R, van Gaalen FA.

Rheumatology (Oxford). 2019 Sep 1;58(9):1649-1654. doi: 10.1093/rheumatology/kez095.

41.

Percentage of progressors in imaging: can we ignore regressors?

Sepriano A, Ramiro S, Landewé R, Dougados M, van der Heijde D.

RMD Open. 2019 Feb 26;5(1):e000848. doi: 10.1136/rmdopen-2018-000848. eCollection 2019.

42.

Measuring spinal mobility in early axial spondyloarthritis: does it matter?

Marques ML, Ramiro S, Goupille P, Dougados M, van Gaalen F, van der Heijde D.

Rheumatology (Oxford). 2019 Sep 1;58(9):1597-1606. doi: 10.1093/rheumatology/kez026.

PMID:
30879078
43.

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.

Humby F, Lewis M, Ramamoorthi N, Hackney JA, Barnes MR, Bombardieri M, Setiadi AF, Kelly S, Bene F, DiCicco M, Riahi S, Rocher V, Ng N, Lazarou I, Hands R, van der Heijde D, Landewé RBM, van der Helm-van Mil A, Cauli A, McInnes I, Buckley CD, Choy EH, Taylor PC, Townsend MJ, Pitzalis C.

Ann Rheum Dis. 2019 Jun;78(6):761-772. doi: 10.1136/annrheumdis-2018-214539. Epub 2019 Mar 16.

44.

Systematic review of rheumatoid arthritis clinical studies: Suboptimal statistical analysis of radiological data.

Mahmood S, van Tuyl L, Schoonmade LJ, Landewé R, van der Heijde D, Twisk J, Boers M.

Semin Arthritis Rheum. 2019 Oct;49(2):218-221. doi: 10.1016/j.semarthrit.2019.02.009. Epub 2019 Feb 21. Review.

PMID:
30878153
45.

A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis.

Deodhar A, Gensler LS, Kay J, Maksymowych WP, Haroon N, Landewé R, Rudwaleit M, Hall S, Bauer L, Hoepken B, de Peyrecave N, Kilgallen B, van der Heijde D.

Arthritis Rheumatol. 2019 Jul;71(7):1101-1111. doi: 10.1002/art.40866. Epub 2019 May 28.

46.

Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.

van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, Fallon L.

J Rheumatol. 2019 Sep;46(9):1089-1096. doi: 10.3899/jrheum.180971. Epub 2019 Mar 1.

47.

Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database.

Ferreira RJO, Carvalho PD, Ndosi M, Duarte C, Chopra A, Murphy E, van der Heijde D, Machado PM, da Silva JAP.

Arthritis Care Res (Hoboken). 2019 Oct;71(10):1317-1325. doi: 10.1002/acr.23866.

PMID:
30821895
48.

HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort.

de Winter JJ, Blijdorp IC, de Jong HM, Sauter J, Schmidt AH, van Gaalen FA, van der Heijde D, Poddubnyy D, Yeremenko NG, van de Sande MG, Baeten DL.

Genes Immun. 2019 Nov;20(8):671-677. doi: 10.1038/s41435-019-0061-4. Epub 2019 Feb 26. Erratum in: Genes Immun. 2019 May 9;:.

PMID:
30809016
49.

Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis Magnetic Resonance Imaging Score (OMERACT JAMRIS-SIJ).

Otobo TM, Conaghan PG, Maksymowych WP, van der Heijde D, Weiss P, Sudol-Szopinska I, Herregods N, Jaremko JL, Meyers AB, Rumsey D, Inarejos EC, Kirkhus E, Stimec J, Panwar J, Thorpe K, Jans L, van Rossum MA, Tolend M, Perez M, Tzaribachev N, Sandhya P, Tse S, Simone A, Swami VG, Touma Z, Lambert R, Doria AS.

J Rheumatol. 2019 Sep;46(9):1192-1197. doi: 10.3899/jrheum.181115. Epub 2019 Feb 15.

PMID:
30770500
50.

Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World.

Kishimoto M, Yoshida K, Ichikawa N, Inoue H, Kaneko Y, Kawasaki T, Matsui K, Morita M, Suda M, Tada K, Takizawa N, Tamura N, Taniguchi A, Taniguchi Y, Tsuji S, Haji Y, Rokutanda R, Yanaoka H, Cheung PP, Gu J, Kim TH, Luo SF, Okada M, López Medina C, Molto A, Dougados M, Kobayashi S, van der Heijde D, Tomita T.

J Rheumatol. 2019 Aug;46(8):896-903. doi: 10.3899/jrheum.180412. Epub 2019 Feb 15.

PMID:
30770497

Supplemental Content

Loading ...
Support Center